|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current Assets | |||||||||||
| Cash | |||||||||||
| Deferred offering costs | |||||||||||
| Prepaid expense | |||||||||||
| Total Current Assets | |||||||||||
| Cash and Marketable Securities held in trust account | |||||||||||
| Total Assets | |||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | |||||||||||
| Current liabilities | |||||||||||
| Accrued expenses | |||||||||||
| Account payable | |||||||||||
| Amount due to related party | |||||||||||
| Franchise tax payable | |||||||||||
| Income tax payable | |||||||||||
| Promissory note – related party | |||||||||||
| Excise tax liability | |||||||||||
| Extension loan | |||||||||||
| Working capital loan | |||||||||||
| Total Current Liabilities | |||||||||||
| Deferred underwriter commission | |||||||||||
| Total Liabilities | |||||||||||
| Class A common stock subject to possible redemption; 1,283,336 shares (at $11.25 and $10.15 per share) | |||||||||||
| Stockholders’ Deficit | |||||||||||
| Common stock, value | |||||||||||
| Common Class A | |||||||||||
| Common Class B | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Total Stockholders’ Deficit | |||||||||||
| Total Liabilities and Stockholders’ Deficit |
Loading...
